Ophthalmology Times

Ophthalmology Times is a publication created by doctors for doctors, providing timely and precise news and insights related to clinical practices, socioeconomic issues, and political developments relevant to the eye care community.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#356664

United States

#142609

Health/Medicine

#1168

Traffic sources

Monthly visitors

Articles

FDA nod for acoltremon: What its approval means for clinicians and patients

21 hours ago | ophthalmologytimes.com | Sheryl Stevenson

Alcon’s announcement of the FDA approval for its acoltremon ophthalmic solution 0.003% (Tryptry; formerly AR-15512) for the treatment of signs and symptoms of dry eye disease (DED)1,2 brings to market a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production.
Q&A: David S. Boyer, MD, on the suprachordial delivery of gene therapy

2 days ago | ophthalmologytimes.com | David S. Boyer |Sydney M Crago

David S. Boyer, MD, discusses a new approach to treating diabetic retinopathy and macular degeneration using suprachoroidal space injections. This innovative technique offers significant advantages over traditional intravitreal injections by providing a less invasive, office-based procedure with dramatically reduced inflammatory risks. Note: The following conversation has been lightly edited for clarity.
ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801

2 days ago | ophthalmologytimes.com | Martin Harp

ViGeneron has rebranded to VeonGen Therapeutics to reflect its evolution into a “clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs.”In addition to the rebranding, VeonGen also announced the US Food and Drug Administration (FDA) has given Rare Pediatric Disease Designation (RPDD) to its lead program, VG801, for the treatment of ABCA4 mutation-associated retinal dystrophy.
Ocugen signs term sheet for korean licensing of OCU400 gene therapy

2 days ago | ophthalmologytimes.com | Martin Harp

Ocugen has announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a “well-established leader in the pharmaceutical and healthcare sector in Korea” for exclusive Korean rights to OCU400. OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).
Kiora Pharmaceuticals and Senju Pharmaceutical partner on KIO-301 for retinal disease treatment in Asia

2 days ago | ophthalmologytimes.com | Martin Harp

Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and commercialization agreement for KIO-301 for the treatment of ophthalmic diseases. Areas covered by the agreement would cover key Asian marketplaces, including Japan and China.
ASCRS 2025: Steven R. Sarkisian Jr., MD, ABO, envisions a future without glaucoma drops

3 days ago | ophthalmologytimes.com | Sheryl Stevenson |Hattie Hayes

Author(s):,At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial. At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting in Los Angeles, California, the Eye Care Network spoke with dozens of presenters about the data they brought to the meeting. Steven R. Sarkisian Jr., MD, ABO, presented data from an FDA clinical trial of a travopost intracameral implant.
Q&A: Rachel Downes, MD, provides highlights from the GATHER1 and GATHER2 clinical trials for GA

5 days ago | ophthalmologytimes.com | Rachel A. Downes |Sydney M Crago

At the 2025 Retina World Congress meeting, held in Fort Lauderdale, Florida from May 8-11, 2025, Rachel Downes, MD, a Vitreoretinal Surgery Fellow at Cleveland Clinic Cole Eye Institute, presented data from the GATHER1 and GATHER2 clinical trials. Ophthalmology Times connected with Downes to learn more about this presentation and the key takeaways. Note: This Q&A has been lightly edited for clarity.
Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD

5 days ago | ophthalmologytimes.com | Martin Harp

Ocular Therapeutix has closed enrollment in its SOL-R registrational trial of its product candidate AXPAXLI (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD). AXPAXLI is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small-molecule, multi-target tyrosine kinase inhibitor (TKI) with anti-angiogenic properties.
Opus Genetics releases topline results from LYNX-2 evaluating phentolamine ophthalmic solution 0.75%

5 days ago | ophthalmologytimes.com | Martin Harp

Opus Genetics has released positive topline results from LYNX-2, its phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Phentolamine ophthalmic solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size.
CCS 2025: Patient journey with neovascular retinal disease through advanced treatment and beyond

1 week ago | ophthalmologytimes.com | Deep Parikh |Emily Kaiser Maharjan

Author(s):,Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease. Editor's note: The below transcript has been lightly edited for clarity. Hi everyone. I'm here with Dr Deep Parikh, who is presenting at the Collaborative Care Symposium on advanced treatments in neovascular retinal disease. Thank you so much for being here, Dr Parikh.